Juvenile dermatomyositis update
Tóm tắt
Recent studies involving juvenile dermatomyositis indicate that the majority of affected children have symptoms suggestive of infection prior to disease onset, damage to skin and muscle each have a distinct pathophysiology, certain urinary muscle metabolites may be useful laboratory markers, and methotrexate used as first line therapy with corticosteroids is associated with greater height velocity and smaller increase in body mass index.
Tài liệu tham khảo
Pachman LM, Lipton R, Ramsey-Goldman R, et al.: History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005, 53:166–172. This study documents the increased incidence of infectious symptoms prior to onset of JDM in a majority of patients.
Mamyrova G, Rider LG, Haagenson L, et al.: Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 2005, 294:2170–2171.
Minetti C, Gattorno M Repetto S, et al.: Chemokine receptor CCR7 is expressed in muscle.bers in juvenile dermatomyositis. Biochem Biophys Res Commun 2005, 333:540–543.
Sakuta R, Murakami N, Jin Y, et al.: Diagnostic signifi- cance of membrane attack complex and vitronectin in childhood dermatomyositis: J Child Neurol 2005, 20:596–602.
Tomono N, Mori M, Nakajima S, et al.: HLA-DRB1*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis. J Rheumatol 2004, 31:1847–1850.
Chung YL, Rider LG, Bell JD, et al.: Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2005, 53:565–570.
Maillard SM, Jones R, Owens CM, et al.: Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005, 53:558–564.
Takken T, van der Net J, Helders PJ: The reliability of an aerobic and an anaerobic exercise tolerance test in patients with juvenile onset dermatomyositis. J Rheumatol 2005, 32:734–739.
Smith RL, Sundberg J, Shamiyah E, et al.: Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004, 31:1644–1649. This study demonstrates the association of nailfold abnormalities and skin involvement, but lack of association with severity of muscle disease.
Fathalla BM, Miller LC, Bubolz B, Schaller JG: Prolonged QTc interval and juvenile dermatomyositis. Clin Exp Rheumatol 2004, 22:788–789.
Akikusa JD, Tennankore, Levin AV, Feldman BM: Eye.ndings in patients with juvenile dermatomyositis. J Rheumatol 2005, 32:1986–1991.
Stock S, Ignatiev K, Lee P, et al.: Pathological calcification in juvenile dermatomyositis (JDM):microCT and synchrotron x-ray diffraction reveal hydroxyapatite with varied microstructures. Connect Tissue Res 2004, 45:248–256.
Alsufyani KA, Ortiz-Alvarez O, Cabral DA, et al.: Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005, 32:729–733.
Ramanan AV, Campbell-Webster N, Ota S, et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52:3570–3357. Although a retrospective study, the data demonstrates the benefit of early use of methotrexate combined with more rapid corticosteroid tapering.
Ambler GR, Chaitow J, Rogers M, et al.: Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005, 32:1837–1839.
Huber A, Feldman BM: Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheum Rep 2005, 7:441–446.